Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, may provide a significant step forward for obesity treatment. Preliminary human tests have indicated considerable decreases in visceral mass , possibly exceeding current obesity therapies . Despite this, additional assessment is needed to fully under